STOCK TITAN

Neurobo Pharmaceuticals Inc SEC Filings

NRBO NASDAQ

Welcome to our dedicated page for Neurobo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading NeuroBo Pharmaceuticals’ clinical disclosures can feel like untangling lab notes—hundreds of pages of receptor pharmacology, trial protocols and risk factors that shift with every phase update. Identifying what really moves the stock, from cash-runway details to management’s option grants, is a challenge even for seasoned analysts.

Stock Titan solves that problem in seconds. Our AI transforms NeuroBo Pharmaceuticals SEC filings explained simply: it condenses the annual report into an easy scan, flags key data in the NeuroBo Pharmaceuticals annual report 10-K simplified, and pairs each NeuroBo Pharmaceuticals quarterly earnings report 10-Q filing with trend visuals on R&D spend. Real-time alerts surface NeuroBo Pharmaceuticals Form 4 insider transactions real-time, while pipeline milestones in every NeuroBo Pharmaceuticals 8-K material events explained arrive on your dashboard moments after hitting EDGAR.

Here’s what you can explore without wading through biotech jargon:

  • Insider activity – track NeuroBo Pharmaceuticals insider trading Form 4 transactions and spot buying patterns before pivotal data drops.
  • Pipeline catalysts – AI highlights trial results, FDA interactions and financing moves within each 8-K.
  • Cash & compensation – compare burn-rate disclosures in 10-Qs with the NeuroBo Pharmaceuticals proxy statement executive compensation to align incentives.
  • Event-driven research – one-click access to NeuroBo Pharmaceuticals earnings report filing analysis and understanding NeuroBo Pharmaceuticals SEC documents with AI.
  • Executive deals – drill into NeuroBo Pharmaceuticals executive stock transactions Form 4 in context with upcoming readouts.

Whether you’re benchmarking dual-agonist competitors or timing entries around Phase 2 data, Stock Titan’s AI-powered summaries, expert commentary and real-time feeds help you move from document download to decision—without missing a disclosure.

Rhea-AI Summary

Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.

Key terms of the grant:

  • Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
  • Change-in-control: The award vests in full upon a change-in-control event.
  • Expiration: May 26 2035 (10-year life).

No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.

Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

Morgan Stanley Finance LLC, guaranteed by Morgan Stanley (ticker MS), is marketing Worst-of INDU and SPX Dual Directional Market-Linked Notes maturing on August 1, 2030. The structured note allocates exposure to the worst performer of the Dow Jones Industrial Average (INDU) and the S&P 500 Index (SPX). Key economic terms include a 100% upside participation rate and a 100% “absolute return” participation on index declines of up to 20%. Positive index performance is capped at 137-140% of principal (maximum cash payment $1,370-$1,400). If the worst performing index closes below the 80% knock-out level on the single observation date (July 29, 2030), principal is fully at risk; the payment then reflects only the indexed return, potentially below par. The notes do not pay coupons and are not listed on any exchange.

The preliminary estimated value is $938.10 per $1,000 note—roughly 6% below issue price—highlighting built-in fees and hedging costs. Investors face issuer and guarantor credit risk, limited secondary liquidity, tax complexity and valuation determined by Morgan Stanley’s internal models. All payments occur at maturity and depend solely on the closing level of the worst index on the observation date; interim movements are irrelevant. The offering is made under Registration Statement Nos. 333-275587 and 333-275587-01, with pricing set for July 28, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

FormFactor Inc. (FORM) has filed a Form 144 notice indicating an intended insider sale of up to 4,000 common shares through Morgan Stanley Smith Barney on or about 01 Jul 2025. Based on the filing’s stated aggregate market value of $136,106.80, the planned transaction represents roughly 0.005 % of the company’s 77,076,642 shares outstanding, implying minimal ownership dilution or trading-volume impact.

The seller, identified in the past-sales table as Mike Slessor, acquired the shares as performance stock on 19 Jul 2022. The document notes no gift status or non-cash consideration. Within the preceding three months, the same individual sold 8,000 shares in two tranches (01 May 2025 and 02 Jun 2025) for combined gross proceeds of $246,188.80. Adding the upcoming sale would bring the rolling three-month total to 12,000 shares.

The filing contains the standard representation that the seller is not in possession of undisclosed material adverse information and provides no indication of additional planned transactions beyond the stated amount. Given the modest size relative to market float and the routine nature of a Rule 144 filing, immediate financial impact appears limited; however, continued insider selling can sometimes influence investor sentiment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

FormFactor Inc. (FORM) has filed a Form 144 notice indicating an intended insider sale of up to 4,000 common shares through Morgan Stanley Smith Barney on or about 01 Jul 2025. Based on the filing’s stated aggregate market value of $136,106.80, the planned transaction represents roughly 0.005 % of the company’s 77,076,642 shares outstanding, implying minimal ownership dilution or trading-volume impact.

The seller, identified in the past-sales table as Mike Slessor, acquired the shares as performance stock on 19 Jul 2022. The document notes no gift status or non-cash consideration. Within the preceding three months, the same individual sold 8,000 shares in two tranches (01 May 2025 and 02 Jun 2025) for combined gross proceeds of $246,188.80. Adding the upcoming sale would bring the rolling three-month total to 12,000 shares.

The filing contains the standard representation that the seller is not in possession of undisclosed material adverse information and provides no indication of additional planned transactions beyond the stated amount. Given the modest size relative to market float and the routine nature of a Rule 144 filing, immediate financial impact appears limited; however, continued insider selling can sometimes influence investor sentiment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Amendment No. 25 to Schedule 13D discloses that India-based Tractors & Farm Equipment Ltd (TAFE), TAFE Motors & Tractors Ltd and chair Mallika Srinivasan collectively hold roughly 16.3 % of AGCO’s 74.6 million outstanding shares (≈12.15 million shares). The filing follows a comprehensive settlement signed on 30 Jun 2025 that resets the long-standing strategic relationship between the two companies.

Key agreements

  • Cooperation Agreement: imposes a perpetual stand-still: the Reporting Persons will vote in line with AGCO’s Board and will not raise their ownership above the “Ownership Cap” (≈16.3 %) except on defined change-of-control triggers. They must also participate proportionately in future AGCO buybacks.
  • Buyback Agreement: AGCO Holding B.V. will sell its 20.7 % stake in TAFE (2.389 million shares) back to TAFE for US$260 million. Completion is pending Indian procedural approvals.
  • Intellectual Property Agreement: Exclusive rights to the “Massey Ferguson” brand for tractors in India, Nepal and Bhutan will transfer to TAFE when the Buyback closes.
  • Arbitration & Litigation Settlements: All cross-border disputes and brand-related suits will be withdrawn, eliminating legal overhang.

Strategic implications

  • AGCO receives US$260 million cash and exits its minority position in TAFE.
  • Stable 16 % shareholder alignment reduces near-term takeover risk and supports Board initiatives.
  • Brand transfer limits AGCO’s direct exposure to the fast-growing Indian tractor market but clarifies marketing rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Amendment No. 25 to Schedule 13D discloses that India-based Tractors & Farm Equipment Ltd (TAFE), TAFE Motors & Tractors Ltd and chair Mallika Srinivasan collectively hold roughly 16.3 % of AGCO’s 74.6 million outstanding shares (≈12.15 million shares). The filing follows a comprehensive settlement signed on 30 Jun 2025 that resets the long-standing strategic relationship between the two companies.

Key agreements

  • Cooperation Agreement: imposes a perpetual stand-still: the Reporting Persons will vote in line with AGCO’s Board and will not raise their ownership above the “Ownership Cap” (≈16.3 %) except on defined change-of-control triggers. They must also participate proportionately in future AGCO buybacks.
  • Buyback Agreement: AGCO Holding B.V. will sell its 20.7 % stake in TAFE (2.389 million shares) back to TAFE for US$260 million. Completion is pending Indian procedural approvals.
  • Intellectual Property Agreement: Exclusive rights to the “Massey Ferguson” brand for tractors in India, Nepal and Bhutan will transfer to TAFE when the Buyback closes.
  • Arbitration & Litigation Settlements: All cross-border disputes and brand-related suits will be withdrawn, eliminating legal overhang.

Strategic implications

  • AGCO receives US$260 million cash and exits its minority position in TAFE.
  • Stable 16 % shareholder alignment reduces near-term takeover risk and supports Board initiatives.
  • Brand transfer limits AGCO’s direct exposure to the fast-growing Indian tractor market but clarifies marketing rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Amendment No. 25 to Schedule 13D discloses that India-based Tractors & Farm Equipment Ltd (TAFE), TAFE Motors & Tractors Ltd and chair Mallika Srinivasan collectively hold roughly 16.3 % of AGCO’s 74.6 million outstanding shares (≈12.15 million shares). The filing follows a comprehensive settlement signed on 30 Jun 2025 that resets the long-standing strategic relationship between the two companies.

Key agreements

  • Cooperation Agreement: imposes a perpetual stand-still: the Reporting Persons will vote in line with AGCO’s Board and will not raise their ownership above the “Ownership Cap” (≈16.3 %) except on defined change-of-control triggers. They must also participate proportionately in future AGCO buybacks.
  • Buyback Agreement: AGCO Holding B.V. will sell its 20.7 % stake in TAFE (2.389 million shares) back to TAFE for US$260 million. Completion is pending Indian procedural approvals.
  • Intellectual Property Agreement: Exclusive rights to the “Massey Ferguson” brand for tractors in India, Nepal and Bhutan will transfer to TAFE when the Buyback closes.
  • Arbitration & Litigation Settlements: All cross-border disputes and brand-related suits will be withdrawn, eliminating legal overhang.

Strategic implications

  • AGCO receives US$260 million cash and exits its minority position in TAFE.
  • Stable 16 % shareholder alignment reduces near-term takeover risk and supports Board initiatives.
  • Brand transfer limits AGCO’s direct exposure to the fast-growing Indian tractor market but clarifies marketing rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamline Health Solutions, Inc. (Nasdaq: STRM) has filed a preliminary Schedule 14A seeking stockholder approval for its $5.34-per-share all-cash merger with Mist Holding Co., the parent of MDaudit. At closing, Merger Sub will merge into Streamline, which will become a wholly-owned subsidiary of MDaudit and cease to be publicly traded.

Key economic terms

  • Cash consideration of $5.34 per share, representing a 138 % premium to the 5/28/25 close and 117 % to the 30-day VWAP.
  • No financing contingency; Parent states it has sufficient cash on hand to fund the deal and related costs.
  • Options and warrants with exercise prices below $5.34 will be cashed-out; all currently outstanding options and warrants are “out-of-the-money” and will be cancelled for no consideration.
  • Termination fee payable by Streamline to Parent is $950 K; no reverse termination fee disclosed.

Governance & process

  • The Streamline Board unanimously approved the merger, deemed it fair, and recommends voting “FOR” all proposals.
  • Cain Brothers rendered a fairness opinion to the Board on 5/28/25.
  • Certain directors and officers entered into Voting & Support Agreements, committing their shares to support the transaction (exact percentage not yet specified).
  • Completion requires the affirmative vote of at least 66 2/3 % of outstanding shares. Failure to vote counts as an “AGAINST.”

Timeline & conditions

  • Special Meeting will be held virtually on a date to be set; record date also to be set.
  • Expected closing is Q3 2025, subject to stockholder approval and customary conditions (no financing or regulatory conditions highlighted).
  • Outside date for termination is 12/31/25.

Post-closing the STRM shares will be delisted from Nasdaq and deregistered under the Exchange Act. Stockholders who properly perfect appraisal rights under Delaware law may seek a court-determined “fair value” instead of the $5.34 cash payment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Neurobo Pharmaceuticals (NRBO)?

The current stock price of Neurobo Pharmaceuticals (NRBO) is $2.36 as of February 7, 2025.

What is the market cap of Neurobo Pharmaceuticals (NRBO)?

The market cap of Neurobo Pharmaceuticals (NRBO) is approximately 20.3M.

What is the primary focus of NeuroBo Pharmaceuticals Inc.?

NeuroBo Pharmaceuticals Inc. is focused on developing innovative therapies for neurodegenerative and cardiometabolic diseases, including obesity, MASH, and diabetic neuropathy.

What therapeutic candidates are currently in NeuroBo's pipeline?

The company is advancing several candidates including DA-1726, a dual GLP1R/GCGR agonist for obesity, DA-1241, a GPR119 agonist for MASH, and NB-01, which is being out-licensed for diabetic neuropathy.

How does DA-1726 work?

DA-1726 is an oxyntomodulin analogue that functions as both a GLP1R and GCGR agonist, aiming to reduce food intake and enhance energy expenditure, which is crucial for achieving weight loss.

What role does DA-1241 play in treating MASH?

DA-1241 acts as a GPR119 agonist to promote the release of gut peptides such as GLP-1, GIP, and PYY, which help improve liver inflammation, lipid metabolism, and glucose control in patients with MASH.

Where is NeuroBo Pharmaceuticals headquartered?

The company is headquartered in Boston, Massachusetts, providing it with access to a strong biotech ecosystem and research community.

How does NeuroBo differentiate itself from other biotech companies?

NeuroBo differentiates itself by focusing on multi-targeted therapeutic approaches, employing dual agonist strategies, and building strong collaborative partnerships to optimize clinical outcomes.

What are the methods used to assess the efficacy of its candidates?

The company uses randomized, placebo-controlled clinical trials, supported by biomarkers, pharmacokinetic and pharmacodynamic studies, to rigorously evaluate safety and therapeutic efficacy.

Why is investor interest generated by NeuroBo Pharmaceuticals?

Investor interest stems from the company’s innovative multi-mechanism approach to challenging medical conditions, its robust research and development process, and its commitment to advancing novel therapeutic candidates.
Neurobo Pharmaceuticals Inc

NASDAQ:NRBO

NRBO Rankings

NRBO Stock Data

20.33M
3.00M
65.24%
12.71%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE